Regulatory challenges of new male contraceptive methods-Reference-Cited by-同舟云学术

Regulatory challenges of new male contraceptive methods

Published:2024-08-02 Issue: Volume: Page:
ISSN:2047-2919
Container-title:Andrology
language:en
Short-container-title:Andrology

Author:

Sitruk‐Ware Regine¹^ORCID,Soule Lisa²,Jarow Jonathan P.³,Odlind Viveca⁴

Affiliation:

1. Center for Biomedical Research, Population Council New York New York USA

2. Bethesda Maryland USA

3. FDA Solutions Bethesda Maryland USA

4. Uppsala Sweden

Abstract

AbstractIntroductionProgress in male contraception development faces the challenge of a lack of regulatory precedent and guidelines on the evidence (trial design and primary endpoint) required for marketing approval. Moreover, the development of a male contraceptive is complicated by the fact that the clinical treatment effect; prevention of pregnancy, is not measured in the patient receiving the intervention.DiscussionRegulatory precedent and guidelines exist for female hormonal contraceptives but their applicability to male contraceptive products likely varies based on the mode of action and the anticipated pharmacodynamic effects of the product. The unique attributes of male contraceptives, including the frequent delay between the intervention (e.g., vasectomy and hormonal methods) and ultimate contraceptive effect, sperm suppression near azoospermia, and pregnancy prevention need to be addressed.ConclusionThis article describes the regulatory challenges faced by developers of male contraceptive products and offers proposals, paving the way for the development of both hormonal methods and non‐hormonal approaches. Our article intends to suggest the directions but cannot substitute for the advice of regulatory agencies.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/andr.13720

Reference28 articles.

1. Food and Drug Administration.Establishing effectiveness and safety for hormonal drug products intended to prevent pregnancy guidance for industry. 2019. Available from:https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/establishing‐effectiveness‐and‐safety‐hormonal‐drug‐products‐intended‐prevent‐pregnancy‐guidance

2. European Medicines Agency.Clinical investigation of steroid contraceptives in women—scientific guideline. 2005. Available from:https://www.ema.europa.eu/en/clinical‐investigation‐steroid‐contraceptives‐women‐scientific‐guideline

3. Food and Drug Administration.FDA guidelines: the extent of population exposure to assess clinical safety: for drugs intended for long‐term treatment of non‐life‐threatening conditions. 1995. Available from:https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/e1a‐extent‐population‐exposure‐assess‐clinical‐safety‐drugs‐intended‐long‐term‐treatment‐non‐life

4. European Medicines Agency.ICH Topic E 1 population exposure: the extent of population exposure to assess clinical safety. 1995. Available from:https://www.ema.europa.eu/en/documents/scientific‐guideline/ich‐e‐1‐population‐exposure‐extent‐population‐exposure‐assess‐clinical‐safety‐step‐5_en.pdf

5. The regulation of spermatogenesis by androgens